Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerDacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancerNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceDrug Resistance to EGFR Inhibitors in Lung CancerThe safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerA Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.Best practice in the treatment of advanced squamous cell lung cancer.Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyTargeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Safety and efficacy of targeted agents monotherapy in advanced NSCLC.Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.Current Role of Dacomitinib in Head and Neck Cancer.Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.The detection of primary and secondary EGFR mutations using droplet digital PCR in patients with nonsmall cell lung cancer
P2860
Q26738986-DBF0462C-A930-42B8-8533-EB9B9E78DB2AQ26745427-7C5F4D63-3D47-48E2-91DF-E55986A6CE25Q26778318-BB0D916C-E966-4920-98CA-42CB29DB4A44Q28075704-4B34506B-E0FE-488B-BA13-8D950C3440E6Q28079320-B3D7BE2F-A3D4-42C4-9125-12AE283E0B1DQ36834883-91FCF2FB-39C3-47F2-81FC-41F373CCFCC9Q37085219-33C8DF5B-51D9-49CC-9AF5-1FE24BA50600Q37225463-251762E9-54D3-4654-8497-2583883ACA5FQ37606650-AAEA6376-7766-4C80-BAE4-37704ED00E8BQ38435967-AAE20AF5-1D1F-48B0-B7EB-86637FB8A06DQ38514601-00B1951F-A7AF-4D11-AB59-F3155ACA875FQ38525856-143F2ADA-B57C-4982-984A-AEB454B3D098Q38585702-B6F363D7-7AC3-4382-9F3F-ED98BA831BC2Q38598893-47F97BC8-D329-41BB-B661-573754BC6B16Q38625550-85635F28-994C-42F4-8A17-FC89B1B554B4Q38630725-01B9EA2D-F74D-425A-856E-8014D5C077BEQ38676692-E3605C11-7C7E-4418-B565-9EE2016C29FCQ38766913-CE43759C-C39E-42BA-B54F-65C22863BAADQ38806115-0C539AFE-B50B-474A-8CB6-DE9D9DFBD4BAQ38829545-48B438F9-E306-471C-AF79-787A0C400FA9Q38936376-73544A8E-7DEA-4F0D-974F-6BE2AAB9596BQ38948950-F2E9A316-3F60-401B-9170-C32CA90BD80AQ38991958-15056EBA-8F25-4D54-8F6C-05920ECE4FD1Q39023478-73041992-F46C-4BD5-A009-0DF06ACC6D39Q39149201-6354BA63-FAD1-46BA-8487-6036BDB87EE3Q41347128-E61990C2-42FE-488D-B87C-8505EA7759EDQ47108431-C4FEED6D-5C86-4888-9DD2-465B46C89F2CQ47574122-094088A3-518B-4FEC-BA2B-52FBF909E383Q53394177-EDBFD827-A318-4EC3-A6A1-8BE6F54A509FQ53838239-1E24BB9B-0122-4F94-83CE-133AD4382E86Q58776683-4C874EB5-8202-4436-AD23-4D34F8C3A5DF
P2860
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Dacomitinib compared with plac ...... nd, randomised, phase 3 trial.
@en
Dacomitinib compared with plac ...... nd, randomised, phase 3 trial.
@nl
type
label
Dacomitinib compared with plac ...... nd, randomised, phase 3 trial.
@en
Dacomitinib compared with plac ...... nd, randomised, phase 3 trial.
@nl
prefLabel
Dacomitinib compared with plac ...... nd, randomised, phase 3 trial.
@en
Dacomitinib compared with plac ...... nd, randomised, phase 3 trial.
@nl
P2093
P50
P1433
P1476
Dacomitinib compared with plac ...... nd, randomised, phase 3 trial.
@en
P2093
Australasian Lung Cancer Trials Group
Byoung Chul Cho
Carolyn F Wilson
Christopher W Lee
Frances A Shepherd
Francesco Perrone
Glenwood D Goss
Jin Hyoung Kang
Keyue Ding
Lesley Seymour
P304
P356
10.1016/S1470-2045(14)70472-3
P577
2014-10-15T00:00:00Z